Reckitt Benckiser Earnings Call: Growth, Margins, Tradeoffs
Reckitt Benckiser Group Plc-ADR ((RBGLY)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Reckitt Benckiser’s latest earnings call struck an overall upbeat tone, with management emphasizing profitable growth, widening margins, and strong momentum in Emerging Markets. At the same time, executives acknowledged pressure points in Europe, seasonal OTC weakness, and a near‑term rise in leverage and taxes that could temper earnings growth through 2026.
Core growth underpinned by balanced pricing and volume
Core Reckitt delivered like‑for‑like net revenue growth of 5.2% in 2025, with volumes up 1.5% and price/mix adding 3.7%, signaling healthy, not purely price‑led expansion. Excluding the drag from seasonal OTC, Core Reckitt grew 7% year on year, showing that the underlying franchises continue to scale despite a soft flu season.
Emerging Markets power ahead with double‑digit gains
Emerging Markets were the clear growth engine, posting 14.6% like‑for‑like net revenue growth and 6.7% volume expansion. Profitability also improved sharply, with adjusted operating margin up 210 basis points to 20.9%, helped by strong momentum in China and India and rising online penetration.
Margins expand as productivity offsets cost inflation
Core Reckitt’s adjusted operating margin expanded by 90 basis points, reflecting successful mix management and efficiency gains. At group level, adjusted operating margin rose 40 basis points to 24.9%, while gross margin ticked up 10 basis points as productivity and savings offset ongoing cost headwinds.
Fuel for Growth unlocks savings to fund brand spend
The Fuel for Growth program delivered substantial cost efficiencies, driving a 150‑basis‑point improvement in fixed costs in 2025. Those savings allowed Reckitt to increase brand equity investment by 120 basis points while still keeping group fixed costs at 19.4% of net revenue, 150 basis points better than last year.
Shareholders rewarded with hefty cash returns
Capital returns were a major highlight, with GBP 2.3 billion handed back to investors via dividends and buybacks in 2025. This included a GBP 1.6 billion special dividend and roughly GBP 900 million of repurchases, and management signaled that buybacks remain a core part of its capital allocation framework.
Innovation pipeline supports premiumization and growth
Reckitt highlighted a strong innovation slate, including the rollout of Durex Intensity to 18 countries and multiple Dettol and Lysol line extensions. The company also secured the first FDA‑approved NDA in the upper‑respiratory category in over 15 years with Mucinex 12‑hour Cold & Fever, underpinning future premium offerings and category expansion.
Mead Johnson shows signs of stabilization
Mead Johnson Nutrition returned to growth, with like‑for‑like net revenue up 3.8% as trade normalized after the 2024 tornado‑related disruption. Adjusted operating margin improved by 150 basis points to 20.4%, supported by rebuilding retailer inventories and more stable market dynamics.
Heavy CapEx backs supply chain scale and resilience
Reckitt lifted capital expenditure to GBP 592 million in 2025, targeting localized, automated, and scalable manufacturing capacity. New Durex lines in Taicang, progress at the Wilson, North Carolina site, and expanded Lysol and Finish capacity are already improving service levels and driving early operational benefits.
Intimate Wellness and Germ Protection lead category growth
Intimate Wellness was the fastest‑growing franchise, up 12.5% like‑for‑like, with Durex posting double‑digit growth and Intima nearly doubling. Germ Protection delivered 8.4% like‑for‑like growth, led by strong double‑digit gains for Dettol in Emerging Markets, highlighting sustained consumer focus on hygiene.
Europe and seasonal OTC drag on performance
Europe remained a weak spot, with net revenue down 1.4% and volumes off 3.1% amid slower category growth, intense promotions, and a soft cold and flu season in Q4. Seasonal OTC declined mid‑single digits, pressuring market share in several key CMUs and exposing Reckitt to volatile winter demand patterns.
North America and Household Care remain sluggish
North America was essentially flat, with like‑for‑like net revenue up just 0.2%, suggesting a more subdued consumer backdrop. Household Care revenues dipped 0.4% like‑for‑like as softness in Europe and North America offset robust Emerging Markets momentum for brands like Finish and Vanish.
EPS held back by FX and higher tax burden
Adjusted diluted EPS rose a modest 1.1% to 352.8p, underscoring that profit growth did not fully translate into per‑share gains. Management flagged that a higher effective tax rate and unfavorable foreign‑exchange movements combined to create roughly a 7% drag on EPS.
Free cash flow pressured by investment and restructuring
Free cash flow came in at GBP 1.7 billion, with conversion at 71%, below historical norms as Reckitt leaned into transformation. One‑off restructuring cash costs and elevated CapEx were the main drivers of the weaker conversion, reflecting a deliberate choice to prioritize long‑term capability building.
Leverage set to rise as divestment and investment bite
Net debt to adjusted EBITDA ended 2025 at 1.6x, or about 2x pro forma the special dividend, but is expected to climb in the near term. Management sees leverage moving toward roughly 2.5x by the first half of 2026 as continued investment coincides with a lower EBITDA base after the Essential Home divestment.
Higher tax rate and stranded costs pose earnings risk
Reckitt guided to an effective tax rate of around 27% for 2026, up from an unusually low prior year, which will cap EPS upside. The Essential Home divestment also leaves stranded costs that Fuel for Growth is expected to largely mitigate by 2026, though fixed costs may rise before easing below 19% by late 2027.
Brand share performance mixed across the portfolio
Only 51% of Core Reckitt’s top CMUs finished the year holding or gaining share, meaning nearly half lost ground. Larger seasonal CMUs such as Mucinex, in particular, saw share slippage in a weak cold and flu season, underscoring the need for sharper execution in mature markets.
Guidance points to steady growth with near‑term headwinds
For 2026, management guided Core Reckitt like‑for‑like net revenue growth of 4–5%, with Q1 running below that range and Emerging Markets again leading. The company expects modest growth at Mead Johnson, rising leverage toward about 2.5x, a higher tax rate around 27%, and fixed costs that temporarily edge up as stranded costs are addressed, while CapEx stays near 4% of sales.
Reckitt’s earnings call painted the picture of a company delivering scalable, margin‑accretive growth while investing heavily for the future and rewarding shareholders. Investors will now focus on how well management navigates European softness, seasonal volatility, higher leverage, and execution on cost savings as the group works to sustain earnings momentum through 2026 and beyond.
